Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.

Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

International journal of endocrinology 5 (45) 2012

Back to issue

One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal insufficiency

Authors: Kothny W., Shao Q., Groop P.H., Lukashevich V.

Categories: Endocrinology

Sections: Specialist manual

print version

Aim. Assess long-term safety and efficacy of the DPP-4 inhibitor vildagliptin in 369 patients with type 2 diabetes (T2DM) and moderate or severe renal insufficiency (RI).

Methods. Double-blind, randomized, parallel-group, 52-week clinical trial comparing safety and efficacy of vildagliptin (50 mg qd, n = 211) and placebo (n = 158) added to ongoing stable antihyperglycemic treatment, in patients with T2DM and moderate or severe (glomerular filtration rate (GFR) ≥ 30 to < 50 mL/min/1.73m2 and < 30 mL/min/1.73m2) RI.

Results. The study population comprised 122 and 89 patients with moderate RI and 94 and 64 patients with severe RI randomized to vildagliptin and placebo, respectively, with the majority of patients receiving background insulin therapy (72 and 82 % for moderate and severe RI, respectively). After one year, the between-treatment difference in adjusted mean change in A1C was –0.4 ± 0.1 % (p = 0.005) in moderate RI (baseline = 7.8 %) and –0.7 ± 0.2 % (p < 0.0001) in severe RI (baseline = 7.6 %). In patients with moderate RI, similar proportions of patients experienced any AE (84 vs. 85 %), any SAE (21 vs. 19 %), any AE leading to discontinuation (5 vs. 6 %) and death (1 vs. 0 %) with vildagliptin and placebo, respectively. This was also true for patients with severe RI: AEs (85 vs. 88 %), SAEs (25 vs. 25 %), AEs leading to discontinuation (10 vs. 6 %) and death (3 vs. 2 %).

Conclusions. In patients with T2DM and moderate or severe RI, vildagliptin added to ongoing antidiabetic therapy had a safety profile similar to placebo during one-year observation. Further, relative to placebo, a clinically-significant decrease in A1C was maintained throughout one-year treatment with vildagliptin.

Diabetes, Obesity and Metabolism. — June 2012

Similar articles

Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
Authors: Body J.-J., Department of Medicine, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium Bergmann P., Department of Radioisotopes, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium; Boonen S., Center for Metabolic Bone Diseases, Katholieke University Leuven, Leuven, Belgium; Devogelaer J.-P., Department of Rheumatology, Saint Luc University Hospital, Universite Catholique de Louvain, Brussels, Belgium; Gielen E., Gerontology and Geriatrics Section, Department of Experimental Medicine, K.U. Leuven, Leuven, Belgium; Goemaere S., Department of Rheumatology and Endocrinology, State University of Gent, Gent, Belgium; Kaufman J.-M., Department of Endocrinology, State University of Gent, Gent, Belgium; Rozenberg S. Department of Gynaecology–Obstetrics, Universite Libre de Bruxelles, Brussels, Belgium; Reginster J.-Y., Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium
"Pain. Joints. Spine." 2 (10) 2013
Date: 2013.08.29
Categories: Family medicine/Therapy, Rheumatology, Traumatology and orthopedics, Therapy
Sections: Specialist manual
Management of patients on dialysis and with kidney transplant during COVID-19 coronavirus infection
Authors: Federico Alberici, Elisa Delbarba, Chiara Manenti, Laura Econimo, Francesca Valerio, Alessandra Pola, Camilla Maffei, Stefano Possenti, Paola Gaggia, Ezio Movilli, Sergio Bove, Fabio Malberti, Marco Farina, Martina Bracchi, Ester Maria Costantino, Nicola Bossini, Mario Gaggiotti, Francesco Scolari on behalf of the “Brescia Renal Covid Task Force”
"Kidneys" Том 9, №2, 2020
Date: 2020.06.03
Categories: Nephrology
Sections: Specialist manual
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome
Authors: Agnes Trautmann, Marina Vivarelli, Susan Samuel, Debbie Gipson, Aditi Sinha, Franz Schaefer, Ng Kar Hui, Olivia Boyer, Moin A. Saleem, Luciana Feltran, Janina Müller-Deile, Jan Ulrich Becker, Francisco Cano, Hong Xu, Yam Ngo Lim, William Smoyer, Ifeoma Anochie, Koichi Nakanishi, Elisabeth Hodson, Dieter Haffner on behalf of the International Pediatric Nephrology Association
"Kidneys" Том 9, №3, 2020
Date: 2020.09.17
Categories: Nephrology
Sections: Official information
Type 2 diabetes mellitus and chronic kidney disease: modern opportunities for antihyperglycemic therapy
Authors: Дідушко О.М.
Івано-Франківський національний медичний університет, м. Івано-Франківськ, Україна

International journal of endocrinology Том 16, №3, 2020
Date: 2020.07.09
Categories: Endocrinology
Sections: Specialist manual

Back to issue